(Q39223286)

English

Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo

scientific article published on 16 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

0 references

(RS)-eflornithine

0 references

trypanosomiasis

0 references

African trypanosomiasis

0 references

Democratic Republic of the Congo

0 references

Republic of the Congo

0 references

object named as

Emilie Alirol

1

0 references

François Chappuis

7

object named as

François Chappuis

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

David Schrumpf

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Josué Amici Heradi

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Andrea Riedel

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Catherine de Patoul

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Michel Quere

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

16 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

195-203

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

The burden of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Human African trypanosomiasis in areas without surveillance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

The trypanosomiases.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Clinical aspects of 2541 patients with second stage human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Difiuoromethylornithine in the treatment of African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Research ethics review in humanitarian contexts: the experience of the independent ethics review board of Médecins Sans Frontières

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Tolerance and safety of nifurtimox in patients with chronic chagas disease

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS886

21 January 2018

Identifiers

10.1093/CID/CIS886

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

release_s7hzvv7ip5fntkd3dehmwfq7wq

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39223286&oldid=2088765936"